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a b s t r a c t
Reduction of low density lipoprotein cholesterol (LDLc) is of vital importance for the
prevention of atherosclerotic cardiovascular disease (ASCVD). Statin is the most effective
therapy today to lower LDLc by inhibiting HMG-CoA-reductase. However despite intensive
statin therapy, there remains a residual risk of recurrent myocardial infarction in about 20–
30% cases. Moreover a few patients develop statin intolerance.
For severe hypercholesterolemia, statins alone or in combination of ezetimibe, niacin
and fenoﬁbrate have been advocated. For homozygous familial hypercholesterolemia
(HOFH), amicrosomal triglyceride transfer proteinMTP inhibitor (Lopitamide) and antisense
oligonucleotide (ASO) (Mipomersen) have recently been approved by FDA, USA through 'Risk
evaluation and Mitigation Strategy (REMS)'. Possible future therapies include PCSK-9 inhi-
bitors which have excellent lipid lowering properties. Three monoclonal antibodies (PCSK 9
Inhibitors) alirocumab, evolocumab and Bococizumab are under advanced clinical stage IV
trials and awaiting approval by FDA and European Medicines Agency.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.1. IntroductionAdult treatment panel (ATP) guidelines of National Cholesterol
Education Programme (NCEP) 20011 established the impor-
tance of lowering 'low density lipoproteins' (LDL) cholesterol
as themainstay of treatment of atherosclerotic cardiovascular
disease (ASCVD). Statins and nonstatins were titrated to a
LDLc goal of 60–80 mg/dl. The ideal principle 'Treat to target'
was recommended and optimal LDLc level was considered 50–
70 mg/dl (<70 mg/dl).2 Cholesterol Treatment Trialist Collabo-
ration3 showed that beneﬁt of statin therapy was tied to
absolute ASCVD risk reduction and absolute lowering of LDLc
levels. Statins are the most effective and validated therapy to
lower LDLc by inhibiting cholesterol synthesis by inhibiting
HMG-CoA reductase.4* Flat No 403, Golden Sobhagya, B-81, Rajendra Marg, Bapu Nagar, Ja
E-mail address: gupta98tanya@gmail.com
http://dx.doi.org/10.1016/j.ihj.2015.05.020
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier2. ObjectiveRecent literaturewas searched on 'novel lipid lowering agents'
which could be used either as alternative monotherapy or in
addition to statins in statin intolerant, high risk ASCVD, non-
familial/familial hypercholesteremia cases and those who
have failed to achieve ideal LDLc goals.
3. MethodsBeside recent journals, we searched Med Pub, Life Sciences
Connect, Mediscape, Cardiosource, AHA/ESC Congress 2014 on
treatment of severe hypercholesterolemia and on PCSK 9
inhibitors.ipur 302 015, India.
B.V. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 4 1 9 – 4 2 44204. Results
Cholesterol treatment guidelines (CTG) to reduce atheroscle-
rotic cardiovascular risk in adults have been recently revised
by American College of Cardiology and American Heart
Association (2013)5 in collaboration with National Heart Lung
and Blood Institute (NHLBI). Four statins beneﬁt group have
been recognized. (i) Individual with clinical atherosclerotic
cardiovascular disease (ASCVD) (ii) Individual with primary
LDLc ≥ 190 mg/dl (iii) Individuals with Diabetes, age 40–75 yrs
with LDLc 70–189 mg/dl but without ASCVD and (iv) Individual
age 40–75yrs without diabetes and without ASCVD with LDLc
70–189 mg/dl and having an estimated CVD risk ≥ 7.5%.
Calculation of CVD risk is based on ACC/AHA risk assessment
equations.6 This group, however, requires clinician patient
discussion.
UK,7 Europe8 and Canada 9 have issued their own
cholesterol treatment guidelines (CTG). ACC/AHA guidelines
(2013) however, do not specify the lipid targets, CTG for
individuals > 75yrs are not clearly outlined.10 ASCVD risk is
often over-estimated by equations advised by ACC/AHA.11
Discussing the implications of CTG 2013 (ACC/AHA), it was
concluded12 that achieving concordance with the new guide-
lines would result in an uniform increase in the use of statins
as well as signiﬁcant reduction in non-statin therapies (like
niacin, ﬁbrates and bile acid sequestrants). In addition, risk
factors like hypertension, diabetes, obesity, smoking etc must
be carefully evaluated along with life style management
strategies.
Monitoring of lipid proﬁle during statin therapy
2013 ACC/AHA guidelines on cholesterol management have
not recommended speciﬁc LDL (c) and non-HDL (c) targets
when the patients has been put on high intensive statin
therapy (e.g. atorvastatin 80 mg/day or rosuvastatin 40 mg/
day). This shift in the management has become a subject of
major controversy.10–12 Many advanced countries follow their
own guidelines.7–9 Even in our country, recent consensus on
management of dyslipidemia in Indian subjects have raised
observations regarding ACC/AHA guidelines and their rele-
vance in Indian population.13 High intensity statin therapy is
intended to reduced CV risk by >50% which is related to
lowering of LDL(c) levels.3 This is consistent with the recent
standards of medical care in diabetes.14 Hence it may be
justiﬁed tomonitor LDL (c) in order to judge CV Risk reduction.
In addition, individual response and tolerability to high
intensity statin therapy may vary considerably. South Asians
including Indians respond differently compared to their
Western counterparts.15 Although statins are pretty safe drugs
but instance of muscle toxicity has been reported in 10–20%
cases. Severe myositis with raised serum creatine phosphoki-
nase (CPK) and even rhabdomyolysis with myoglobinuria and
raised serum creatinine have been described. Under such
circumstance of statin intolerance, alternative lipids lowering
drugs are required.
PROVE IT, TIMI-22 Trial has provided uncontroversial data
to prove the beneﬁcial effects of intensive lipid lowering in
acute coronary syndrome and diabetes.16 However about 20%patients on maximally tolerated statins therapy continue to
exhibit residual cardiovascular risk. The CV risk is reduced
considerably but not to zero. Further, optimal LDLc target of
<70 mg/dl may not be achieved. Another 15–20% patient
develop statin intolerance in the form of mild to severe
muscular pain, tenderness, cramps, stiffness, fatigue etc with
or without raised creatine phosphokinase (CPK) levels. If
symptoms improve on stoppage of statin and reappear on its
resumption, statin intolerance is clinically considered. Many
comorbidities predispose individuals to adverse effects of
statins. A few of them include renal/hepatic insufﬁciency,
raised transaminases, past history of hemorrhagic stroke and
statin intolerance. Under these conditions alternative treat-
ment may be required with or without statins.
AIM HIGH INVESTIGATORS (2011)17 administered Niacin in
addition to statins to raise HDLc and lower LDLc to prevent
adverse CV events. Additional beneﬁts with niacin could not
be established. Relationship between Niacin, lipoproteins and
cardiovascular outcomehas been studied in 3196 patientswith
established atherosclerotic cardiovascular disease. 1440 were
given extended release niacin (ER NIACIN) 1500–2000 mg in
addition to statins with or without ezetimibe. The patients
were followed for three years with treatment. Niacin could not
achieve additional clinical beneﬁt over statin group despite a
15% higher High Density Lipoprotein (HDL) cholesterol level in
group receiving Niacin.18
IMPROVED REDUCTION OF OUTCOME VYTORIN EFFICACY
INTERNATIONAL TRIAL (IMPROVE IT)19 studied the efﬁcacy of
'ezetimibe' when added to simvastatin. A total of 18444
patients were randomized at 1158 centers in 39 countries; 9067
were given ezetimibe (10 mg) plus simvastatin (40 mg) while
9077 received simvastatin (40 mg) orally. Baseline clinical and
biochemical data were almost identical in the two groups and
their mean basal LDLc was 95 mg/dl. After one year of therapy,
mean LDLc levels in the two groups were 53.7 mg/dl and
69.7 mg/dl respectively. However the primary end point of CV
death, myocardial infarction (MI) or unstable angina (UA) or
stroke was signiﬁcantly lower in ezetimibe PLUS simvastatin
group (20.4%) compared with simvastatin alone group (22.2%).
IMPROVE IT trial concluded that addition of ezetimibe
produced lower LDLc and better CV end results than
simvastatin alone. Trial also conﬁrmed the earlier notion
about LDLc ‘‘the lower the better’’.
5. Recently approved therapies for
homozygous familial hypercholesterolemia (HOFH)Microsomal triglyceride transfer protein (MTTP) inhibitor
'LOMITAPIDE' (Aegerion Pharmaceuticals, USA) and Apopro-
tein B (Apo B) antisense oligonucleotide (ASO) 'Mipomersen'
(Kynamro Genzyme Corporation, USA) have been recently
approved by FDA, for restricted use in HOFM through Risk
Evaluation and Mitigation Strategy (REMS) since their safety
has not been fully evaluated. Lomitapide but not Mipomersen
has been approved by European Medicines Agency for HOFH
only. Both drugs are prohibitively costly.
Microsomal triglyceride transfer protein (MTTP) inhibitor
'Lomitapide' inhibits the production of Apo-B resulting
in diminished secretion of chylomicrons, VLDL and LDL. The
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 4 1 9 – 4 2 4 421efﬁcacy and safety of Lomitapide has been studied in 29 HOFH
patients.20 The drug was given in the increasing doses from 5
to 60 mg/day for 26 weeks and followed till 78 weeks for safety
assessment. 23 patients completed 78 weeks of study with a
median dose of 40 mg/day along with statin and nonstatin
drugs. Mean LDLc diminished from baseline of 336 mg/dl to
166 mg/dl at 26 weeks but increased to 208 mg/dl at 78 weeks.
The side effects were nausea, diarrhea and raised transami-
nases.
Antisense oligonucleotide (ASO) 'mipomersen' binds with
RNA of Apo-B in the liver and reduces the synthesis of all
lipoproteins including LDLc. Mipomersen was studied in 158
hypercholesterolemic patientswith baseline LDLc>100 mg/dl,
who were receiving maximally tolerated lipid lowering
therapy.21 Patients received weekly subcutaneous mipomer-
sen 200 mg (n = 105) or placebo (n = 52) for 26 weeks with a 24
weeks follow up; 60 on mipomersen and 44 on placebo
completed 50weeks.Mean baseline LDLc levelswere 122.6 mg/
dl and 122.7 mg/dl in the mipomersen and placebo groups
respectively. Mipomersen reduced LDLc by 36.9% compared
with 4.5% in placebo group. Side effectswithmipomersenwere
skin reaction at injection site (78%), ﬂu like symptoms (34%)
and raised transaminases (10%). Of 54 patients who discon-
tinued, 45 were in the mipomersen group and 9 in placebo
group. Hence, mipomersen appears toxic for routine use.
Both above drugs not recommended for nonfamilial
hypercholesterolemia.
6. Future therapy – PCSK 9 inhibitorsProprotein convertase subtilisin/Kexin 9 (PCSK-9) is an enzyme
discovered in 2003. It is encoded by PCSK-9 gene. It is chieﬂy
expressed in the liver and intestines. PCSK-9 is an inhibitor of
LDL receptors (LDL R) which is a preferential pathway through
which LDLc is normally cleared from the blood. LDLc gets
bound to LDL (R) on the surface of liver cells and then
internalized into the liver cells where LDL is further metabo-
lized while LDL(R) returns back to the surface of liver cells for
further interaction the LDLc. This process continues for several
cycles. PCSK 9 binds with LDL(R) on the surface of liver cells
and promotes degradation of LDL(R) in the liver cells by the
lysozyme pathway and prevents its recycling back to the liver
cell surface.
PCSK 9 inhibitors inhibit the binding of PCSK 9 with LDL(R)
and prevent the degradation of LDL(R) which is thus available
to mop more LDLc for metabolism. It was observed that a rare
'gain of function' by gene mutation of PCSK 9 leads to severe
elevation of LDLc and premature ASCVD whereas rare 'loss of
function' by gene mutation of PCSK 9 reduces LDLc and
decreases the incidence of ASCVD.22 This research provided
impetus and rational to develop PCSK 9 inhibitors to lower
LDLc. Elevated serum levels of PCSK 9 have been reported
during statin therapy and in familial hypercholesterolemia.
Elevated plasma PCKS 9 levels is equally detrimental for
patients with nonfamilial hypercholesterolemia and hetero-
zygous familial hypercholesterolemia, irrespective of LD(R)
defects.23 PCSK 9 inhibitors restore the activity of LDL(R) and
reduce LDLc. Three monoclonal antibodies have emerged as
prominent PCSK 9 inhibitors.24–26 These are alirocumab(Aventis/Regeneron), Evolocumab (Amgen) and bococizumab
(Pﬁzer). The ﬁrst two have undergone considerable clinical
research and are in advanced stage for approval by FDA. These
monoclonal antibodies are administered subcutaneously once
in two weeks or monthly which reduces LDLc by over 50% in
most patients. LDLc may get markedly reduced down to 25–
40 mg/dl in few cases. A doubt of neurological adverse effects
has been raised in such cases, especially of hemorrhagic stroke
when LDLc <25–30 mg/dl.
Evolucumab is a fully humanmonoclonal antibody. Phase I
and II trials27–29 showed that evolocumab is able to reduce
LDLc from 40 to 80%, apolipoprotein B from 30 to 59% and
lipoprotein A from 18 to 36%. The reduction of LDLc is on
monotherapy as well as when given with statins and the
reduction is dose dependent. There were few side effects
limited to nasopharyngitis, local skin reaction at injection site
and arthralgia. MANDEL-230 Phase III clinical trial was anti-
PCSK-9monotherapy for hypercholesterolemia in 614 patients
whowere randomly assigned to Evolocumab (n = 306), placebo
(n-155) and ezetimibe (n = 154). Evolocumab was given 140 mg
once in two weeks (n = 153) or 420 mg once a month (n = 163).
LDLc decreased from baseline on average by 56% in compari-
son with 17.8% with ezetimibe and <1% on placebo. Serious
side effects encountered with evolocumab were acute pan-
creatitis (one patient) and raised transaminases (one patient).
GAUSS2 randomized placebo controlled trial31 studied the
role of Evolocumab in 307 statin intolerant patients with
severe muscle related side effects. Evolocumab was given
140 mg once in two weeks or 420 mg once a month to 205
patients while ezetimibe was given to 102 patients (control).
Baseline LDLc was 193  59 mg/dl. Evolocumab achieved
signiﬁcant 56.1% reduction of LDLc in comparison to 36.9%
with ezetimibe. 282 subjects were studied32 in LAPLACE-TIMI
57 (LDLc Assessment with PCSK-9 monoclonal antibody
(AMG145) Inhibition combined with statin therapy Thrombol-
ysis in Myocardial Infarction) at high CV risk according to
NCEP-ATP III criteria. Over 90% patients achieved NCEP-ATP III
goal of LDLc <70 m/dl, non HDLc <100 mg/dl and Apo
B < 80 mg/dl. The efﬁcacy and safety of long term evolocumab
in hypercholesterolemia patients has been recently analyzed
in Open Label Study of Long Term Evaluation of Evolocumab
against LDLc (OSLER) randomized trial.33
Further studies on Evolocumab are in progress under
PROFICID (Programme to reduce LDLc and cardiovascular
outcomes following Inhibition of PCSK 9 in different popula-
tions) at 22 centers.34 RUTHERFORD-2 dealswith Heterozygous
Familial Hypercholesteremia (49 patients) and FOURIER
(Further cardiovascular Outcome Research with PCSK-9
inhibitors) to analyze the long term safety and efﬁcacy in
about 27000 patients in many countries of the world. Telsa
Study35 deals with 8 patients of HOFH treated with Evolocu-
mab (AMG 145).
Alirocumab (REGN 727) is another monoclonal antibody
discovered by the scientiﬁc teamof Aventis/Regeneron, USA. It
is a PCSK 9 inhibitor and protects LDL(R) from degradation in
the liver. It has been used as monotherapy as well as in
combination with statins and ezetimibe and has shown
remarkable reduction in LDLc in nonfamilial and familial
hypercholesterolemia.36–38Table 1 summarizes the results of a
few published trials on PCKS 9 inhibitors. Recent trials with
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i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 4 1 9 – 4 2 4422alirocumab include Odyssey FH1 and FH2, Odyssey Combo and
Odyssey Long Term Trial. These are Phase 3 and Phase 4 trials.
7. Odyssey FH1 and FH2Familial hypercholesterolemia is due to genetic mutation of
gene resulting in either absence or defective LDL(R). There is
excessive cumulative load of LDLc leading to premature
ASCVD.
In homozygous familial hypercholesterolemia (HOFH),
LDL(R) is either totally absent or grossly defective due to
two identical mutations while in heterozygous familial
hypercholesterolemia (HeFH), LDL(R) is defective but not
totally absent due to singlemutation. InHOFH, LDLc is usually
markedly raised (>500 mg/dl), while in HeFH > 190–400 mg/
dl. The ASCVD outcome is seriously affected due to raised
LDLc. Alirocumab inhibits PCSK 9 and preserves LDL(R) and
reduces LDLc in HeFH. In HOFH, alirocumab may be helpful if
LDL(R) is only defective but not absent. Odyssey FH1 and FH2
are being conducted simultaneously in N America, Europe
and S Africa and includes 735 HeFH patients. Alirocumab is
given in dose of 75 mg once in two week. 40% required
upgradation of dose to alirocumab to 150 mg once in two
weeks. LDLc reduction with alirocumab has been signiﬁcant
(49%) and sustained.
Odyssey Combo Trial includes 720 hypercholesterolemia
patients with high CV risk and inadequately controlled by
maximally tolerated statins plus ezetimibe. 479 of them were
given alirocumab (either 75 or 150 mg once in two weeks),
while the remaining 241 continued on statin plus ezetimibe.
Results are awaited.
Odyssey Long Term Trial has included 2341 patients,
mean age 64yrs, 37% women, 35% diabetics and mean BMI
30 kg/m2. 18% patients were HeFH. All patients had elevated
LDLc and high CV risk. Mean basal LDLc on maximally
tolerated statin was 122 mg/dl. Out of 2341 cases, 1553
received alirocumab 150 mg once in two weeks while 788
served as control. After 65 weeks, 81% patients on alirocu-
mab achieved mean LDLc of 50 mg/dl. There was 54%
reduction in major adverse CV events (MACE) deﬁned as
CV death, MI, stroke or UA requiring hospitalization.
Discontinuation of therapy was 6.2% with alirocumab versus
5.5% in controls.39
CHOICE I and CHOICE II are ongoing trials to analyze
frequency of doses of alirocumab either once in two weeks or
once in a month.
Bococizumab is a PCSK 9 inhibitor sponsored by Pﬁzer. The
drug is under research in Phase 2/3 under SPIRE 1 and SPIRE 2.
Bococizumab (RN316) is reported to signiﬁcantly reduce LDLc
in statin treated patients with high cholesterol in Phase 2(b)
study presented at ACC in March 2014. The drug was given
subcutaneously in doses of 150 mg once in two weeks or
300 mg once a month. The mean decrease in LDLc from the
baseline at 12 weeks was 53.4 mg/dl with 150 mg dose and
44.9 mg/dl with 300 mg dose of bococizumab. Phase III clinical
trial of bococizumab is likely to involve many more patients
and is divided into SPIRE (HF) with HeFH cases, SPIRE (HR) with
very high CV Risk and SPIRE-LDL. The results are likely to be
available in 2016–2018.
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 4 1 9 – 4 2 4 4238. ConclusionToday statins are the most validated and effective therapy in
lowering LDLc in clinical practicewith aview to reduceASCVD
and adverse CV events. However in about 20% patients,
statins fail to achieve the desired LDLc target of <70 mg/dl;
and a few patients are unable to tolerate statins. Further CV
events do recur inspite of effective statin therapy.Under these
circumstances, additional therapy with ezetimibe may be
beneﬁcial. PCSK 9 inhibitors have excellent lipid lowering
properties and beneﬁcial effect on CV outcome. Evolocumab
and Alirocumab have entered Phase IV clinical trials on their
long term safety. If found cost effective and safe on long
termbasis, PCSK 9 inhibitorsmay prove invaluable in treating
hypercholesterolemia of varying aetiologies. PCSK 9 inhibi-
tors still await approval by FDA, European Medicines
Agency and other medicine controlling authorities in various
countries.
PCSK9 inhibitors are not intended for primary prevention in
general public. The possible indications could be as follows:1. Patients suffering from homozygous familial hypercholes-
terolemia (HOF H) and heterozygous familial hypercholes-
terolemia (HeFH)2. Non familial hypercholesterolemia patients who are se-
verely statin intolerant (secondary prevention).3. As a research tool.
PCSK 9 inhibition is a new concept in the management of
cholesterol. Till now, the emphasis was either reduced
cholesterol intake or reduced cholesterol synthesis. PCSK 9
inhibitors inhibit the binding of PCSK 9 enzyme with LDL
receptors and prevent degradation of LDL receptor. Thus LDL
receptor is available to bind with LDL(c) and its disposal by
hepatocytes.
Administration of PCSK 9 inhibitors by subcutaneous route
may cause skin discomfort and local reaction. Trials under-
taken so far have not reported any major side effects during
the study periods varying 6–18months. Further ongoing
research on the development and reﬁnement of PCSK 9
inhibitors may culminate in the synthesis of safer and more
acceptable analogs. Since the drugs are yet notmarketed, their
cost is not known. Long term safety and cost effectiveness are
important factors to decide the future of this innovative
treatment. The research for new acceptable analogs must
continue if we desire purposeful results.
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